Danaher reports Q3 2026 earnings up 34.5%, raises full-year EPS guidance to $8.57-$8.62

Danaher Corporation reported strong Q3 2026 results with net earnings rising 34.5% year-over-year to $1.2 billion, or $1.71 per diluted share. Revenues increased 8.5% to $6.6 billion, driven by core growth excluding respiratory revenue. The company raised its full-year adjusted EPS guidance to $8.57-$8.62, citing improving demand and operational execution. Danaher aims to lead in Life Sciences and Diagnostics, focusing on sustainable growth and patient outcomes.

Danaher Corporation shares are trading at USD 225.65 on Pluang as of Oct 21, 2026 17:11 WIB, showing a modest 0.73% increase for the day. The stock's market capitalization stands at $157.64 billion, reflecting its significant presence in the health sector. Despite strong earnings and raised guidance, Pluang order activity currently leans heavily towards selling at 79%.